Neuphoria Therapeutics (NEUP) Accumulated Depreciation & Amortization (2021 - 2024)
Neuphoria Therapeutics (NEUP) reported Accumulated Depreciation & Amortization of $45722.0 for Q2 2024, up 1.12% year-over-year from $45216.6 in Q3 2023, and up 1.12% on a QoQ basis from $45216.6 in Q2 2023.
Neuphoria Therapeutics (NEUP) has 3 years of Accumulated Depreciation & Amortization data on file, last reported at $45722.0 in Q2 2024.
- Quarterly Accumulated Depreciation & Amortization rose 1.12% year-over-year to $45722.0 in Q2 2024, while the trailing twelve-month figure through Jun 2024 was $45722.0 (up 1.12% YoY) and the FY2024 annual result came in at $45722.0, up 1.07% from the prior year.
- Accumulated Depreciation & Amortization grew to $45722.0 in Q2 2024 per NEUP's latest filing, from $45216.6 in the prior quarter.
- Across five years, Accumulated Depreciation & Amortization topped out at $82205.7 in Q2 2021 and bottomed at $45216.6 in Q2 2023.
- The 3-year median for Accumulated Depreciation & Amortization is $45722.0 (2024), against an average of $57714.8.
- Peak annual rise in Accumulated Depreciation & Amortization reached 1.12% in 2024, while the deepest fall reached 1.12% in 2024.
- Tracing NEUP's Accumulated Depreciation & Amortization over 3 years: stood at $82205.7 in 2021, then plunged by 45.0% to $45216.6 in 2023, then increased by 1.12% to $45722.0 in 2024.
- Per Business Quant, the three latest NEUP Accumulated Depreciation & Amortization figures stand at $45722.0 (Q2 2024), $45216.6 (Q2 2023), and $82205.7 (Q2 2021).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Neuphoria Therapeutics | 28.35 Mn | 8.95 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 45,722.00 |
| Jun 30, 2024 | 45,722.00 |
| Jun 30, 2023 | 45,216.56 |
| Jun 30, 2023 | 45,216.56 |
| Jun 30, 2021 | -75,870.45 |
| Jun 30, 2021 | -75,870.45 |